SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company's operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due to the size and scale of the Plasma business unit. It aggregates components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:

•Japan

•EMEA

•North America Plasma

•All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics.

The Company measures and evaluates the operating segments based on operating income. It excludes certain corporate expenses from segment operating income. In addition, certain amounts that the Company considers to be non-recurring or non-operational are excluded from segment operating income because it evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, PCS2 accelerated depreciation and related costs and certain legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. The Company measures and evaluates its net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

During fiscal 2019, the Company reorganized its operating segments such that certain immaterial components of EMEA are now reported as components of All Other. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2019. These changes did not have an impact on the Company's ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.

Selected information by business segment is presented below:



(In thousands)	2019			2018			2017
Net revenues
Japan	$	70,227		$	68,172		$	74,695
EMEA	169,862			173,551			188,907
North America Plasma	395,922			333,831			309,718
All Other	337,054			333,763			326,260
Net revenues before foreign exchange impact	973,065			909,317			899,580
Effect of exchange rates	(5,486		)	(5,394		)	(13,464		)
Net revenues	$	967,579		$	903,923		$	886,116



(In thousands)	2019			2018			2017
Segment operating income
Japan	$	36,226		$	40,193		$	43,042
EMEA	49,730			68,897			74,878
North America Plasma	167,205			129,697			109,889
All Other	141,070			140,623			141,427
Segment operating income	394,231			379,410			369,236
Corporate operating expenses	(237,568		)	(252,222		)	(249,048		)
Effect of exchange rates	8,367			4,059			(4,772		)
Restructuring and turnaround costs	(13,660		)	(44,125		)	(34,337		)
Deal amortization	(24,803		)	(26,013		)	(27,107		)
Impairment of assets	(21,170		)	(1,941		)	(73,353		)
Legal charges	(2,726		)	(3,011		)	—
PCS2 accelerated depreciation and related costs	(19,126		)	—			—
Operating income (loss)	$	83,545		$	56,157		$	(19,381	)



(In thousands)	2019		2018		2017
Depreciation and amortization
Japan	$	520	$	486	$	827
EMEA	4,153		4,464		4,255
North America Plasma	39,497		16,060		13,022
All Other	65,248		68,237		71,629
Total depreciation and amortization (excluding impairment charges)	$	109,418	$	89,247	$	89,733



(In thousands)	March 30, 2019		March 31, 2018		April 1, 2017
Long-lived assets⁽¹⁾
Japan	$	26,660	$	26,640	$	21,412
EMEA	71,048		74,783		63,854
North America Plasma	113,921		91,815		142,164
All Other	132,350		138,918		96,432
Total long-lived assets	$	343,979	$	332,156	$	323,862
⁽¹⁾ Long-lived assets are comprised of property, plant and equipment.

Selected information by principle operating regions is presented below:



(In thousands)	2019		2018		2017
Net Revenues
United States	$	606,845	$	548,731	$	522,686
Japan	69,908		67,319		79,266
Europe	164,504		164,226		166,007
Asia	118,700		115,127		109,858
Other	7,622		8,520		8,299
Net revenues	$	967,579	$	903,923	$	886,116



(In thousands)	March 30, 2019		March 31, 2018		April 1, 2017
Long-lived assets⁽¹⁾
United States	$	269,849	$	236,603	$	241,610
Japan	1,726		1,511		1,691
Europe	11,200		13,696		12,952
Asia	30,930		36,431		34,174
Other	30,274		43,915		33,435
Total long-lived assets	$	343,979	$	332,156	$	323,862
⁽¹⁾ Long-lived assets are comprised of property, plant and equipment.

The Company's products are organized into three categories for purposes of evaluating their growth potential: Plasma, Blood Center and Hospital. Management reviews revenue trends based on these business units.

Net revenues by business unit are as follows:



(In thousands)	2019		2018		2017
Plasma	501,837		435,956		410,727
Blood Center	269,203		284,902		303,890
Hospital	196,539		183,065		171,499
Net revenues	$	967,579	$	903,923	$	886,116